AINDEX
Markets

Alvotech (ALVOW)

ALVOWNASDAQ-GMBiotechnology: Biological Products (No Diagnostic Substances)

$0.2753

0.0000 (0.00%) today

Closed, Nov 13, 10:00 AM ET

– 1D
Market cap
$107.49m
P/E
–
EPS, last 4 quarters
–
Dividend yield
–
Day range
–
52-week range
$0.1188 to $1.05
Average volume
–
Previous close
$0.2753

Financials

No quarterly figures from the source.

News

8 latest

The company

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer.

Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ-GM
Region
Europe

Often looked at with it

Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.